{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:37Z","timestamp":1793946517397,"version":"4.8.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104714"],"award-info":[{"award-number":["82104714"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007765","name":"Shenyang Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["24-214-3-176"],"award-info":[{"award-number":["24-214-3-176"]}],"id":[{"id":"10.13039\/501100007765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.exer.2026.111278","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:43:18Z","timestamp":1791416598000},"page":"111278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in long-acting ocular therapies for dry eye disease: Delivery systems, formulations, and clinical perspectives"],"prefix":"10.1016","volume":"273","author":[{"given":"Zixuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0443-1142","authenticated-orcid":false,"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.exer.2026.111278_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jtos.2019.02.010","article-title":"Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics","volume":"17","author":"Agarwal","year":"2019","journal-title":"Ocul. Surf."},{"issue":"7","key":"10.1016\/j.exer.2026.111278_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202100043","article-title":"Preparation of nanoparticle-containing ring-implanted Poly(Vinyl alcohol) contact lens for sustained release of hyaluronic acid","volume":"21","author":"Akbari","year":"2021","journal-title":"Macromol. Biosci."},{"issue":"3","key":"10.1016\/j.exer.2026.111278_bib3","first-page":"193","article-title":"Recent patents on ophthalmic nanoformulations and therapeutic implications","volume":"8","author":"Ako-Adounvo","year":"2014","journal-title":"Recent Pat DrugDelivFormul"},{"key":"10.1016\/j.exer.2026.111278_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaophthalmol.2023.0709","article-title":"Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial","volume":"141","author":"Akpek","year":"2023","journal-title":"JAMA Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2026.111278_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1021\/acsbiomaterials.3c01144","article-title":"Enhancing ocular drug delivery: the effect of physicochemical properties of nanoparticles on the mechanism of their uptake by human cornea epithelial cells","volume":"10","author":"Azadi","year":"2024","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"10","key":"10.1016\/j.exer.2026.111278_bib6","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s40123-025-01217-9","article-title":"Assessment the safety of CyclASol compared with vehicle and commercially available 0.05% cyclosporine in dry eye disease: a systematic review and meta-analysis","volume":"14","author":"Ballesteros-S\u00e1nchez","year":"2025","journal-title":"Ophthalmol. Ther."},{"issue":"5","key":"10.1016\/j.exer.2026.111278_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5301\/ejo.5000952","article-title":"A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye","volume":"27","author":"Baudouin","year":"2017","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.exer.2026.111278_bib9","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.3390\/pharmaceutics13122050","article-title":"Stimuli-responsive polymers for transdermal, transmucosal and ocular drug delivery","volume":"13","author":"Berillo","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.exer.2026.111278_bib10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ajo.2015.05.013","article-title":"Punctal plug retention rates for the treatment of moderate to severe dry eye: a randomized, double-masked, controlled clinical trial","volume":"160","author":"Brissette","year":"2015","journal-title":"Am. J. Ophthalmol."},{"issue":"19","key":"10.1016\/j.exer.2026.111278_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202200678","article-title":"In situ forming hydrogel as a tracer and degradable lacrimal plug for dry eye treatment","volume":"11","author":"Dai","year":"2022","journal-title":"Adv. Healthcare Mater."},{"issue":"8","key":"10.1016\/j.exer.2026.111278_bib12","first-page":"1087","article-title":"Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases","volume":"106","author":"Deshmukh","year":"2022","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2026.111278_bib13","first-page":"60","article-title":"An overview of in situ gelling systems","volume":"3","author":"Devasani","year":"2016","journal-title":"Pharmaceut. Biol. Evaluat."},{"key":"10.1016\/j.exer.2026.111278_bib14","author":"Dou"},{"issue":"3","key":"10.1016\/j.exer.2026.111278_bib15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/pharmaceutics13030360","article-title":"Cyclosporine lipid nanocapsules as thermoresponsive gel for dry eye management: promising corneal mucoadhesion, biodistribution and preclinical efficacy in rabbits","volume":"13","author":"Eldesouky","year":"2021","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.exer.2026.111278_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/jop.2022.0031","article-title":"Effectiveness of topical cyclosporin A 0.1%, diquafosol tetrasodium 3%, and their combination, in dry eye disease","volume":"38","author":"Eom","year":"2022","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.exer.2026.111278_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/jop.2022.0119","article-title":"A multicenter, randomized, double-blind evaluation of the efficacy of TJO-087 versus 0.05% cyclosporine A in moderate to severe dry eye","volume":"39","author":"Eom","year":"2023","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"issue":"22","key":"10.1016\/j.exer.2026.111278_bib18","doi-asserted-by":"crossref","first-page":"8756","DOI":"10.3390\/ijms21228756","article-title":"TRPM8: a therapeutic target for neuroinflammatory symptoms induced by severe dry eye disease","volume":"21","author":"Fakih","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.exer.2026.111278_bib19","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.3390\/ma14247541","article-title":"Development and characterization of nanoemulsions for ophthalmic applications: role of cationic surfactants","volume":"14","author":"Fernandes","year":"2021","journal-title":"Materials"},{"key":"10.1016\/j.exer.2026.111278_bib20","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2147\/OPTH.S187963","article-title":"Cross-linked hyaluronic acid gel occlusive device for the treatment of dry eye syndrome","volume":"12","author":"Fezza","year":"2018","journal-title":"Clin. Ophthalmol."},{"issue":"5","key":"10.1016\/j.exer.2026.111278_bib21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","article-title":"Recent perspectives in ocular drug delivery","volume":"26","author":"Gaudana","year":"2009","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.exer.2026.111278_bib22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1124\/jpet.119.256933","article-title":"Ocular drug delivery: present innovations and future challenges","volume":"370","author":"Gote","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"7","key":"10.1016\/j.exer.2026.111278_bib23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/ICO.0000000000003477","article-title":"Immediate and delayed effects of punctal plug insertion on tear meniscus height in severe aqueous-deficient dry eye","volume":"43","author":"Hallali","year":"2024","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.exer.2026.111278_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00418-006-0246-6","article-title":"MUC16 in the lacrimal apparatus","volume":"127","author":"Jager","year":"2007","journal-title":"Histochem. Cell Biol."},{"issue":"6","key":"10.1016\/j.exer.2026.111278_bib25","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3109\/10837450.2014.910807","article-title":"Development and evaluation of a novel in situ gel of sparfloxacin for sustained ocular drug delivery: in vitro and ex vivo characterization","volume":"20","author":"Khan","year":"2015","journal-title":"Pharmaceut. Dev. Technol."},{"issue":"1","key":"10.1016\/j.exer.2026.111278_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2010.07.119","article-title":"Extended release of dexamethasone from silicone-hydrogel contact lenses containing vitamin E","volume":"148","author":"Kim","year":"2010","journal-title":"J. Contr. Release"},{"issue":"2","key":"10.1016\/j.exer.2026.111278_bib27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.exer.2026.111278_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/604204","article-title":"Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb","volume":"2012","author":"Lallemand","year":"2012","journal-title":"J. Drug Deliv."},{"issue":"4","key":"10.1016\/j.exer.2026.111278_bib29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.exer.2026.111278_bib30","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1021\/ie0507934","article-title":"Modeling ophthalmic drug delivery by soaked contact lenses","volume":"45","author":"Li","year":"2006","journal-title":"Ind. Eng. Chem. Res."},{"issue":"1","key":"10.1016\/j.exer.2026.111278_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2184312","article-title":"Physicochemical properties and micro-interaction between micro-nanoparticles and anterior corneal multilayer biological interface film for improving drug delivery efficacy: the transformation of tear film turnover mode","volume":"30","author":"Li","year":"2023","journal-title":"Drug Deliv."},{"issue":"7","key":"10.1016\/j.exer.2026.111278_bib32","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1523\/JNEUROSCI.3632-04.2005","article-title":"Functional control of cold-and menthol-sensitive TRPM8 ion channels by phosphatidylinositol 4, 5-bisphosphate","volume":"25","author":"Liu","year":"2005","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.exer.2026.111278_bib33","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/ICO.0000000000001989","article-title":"Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with Keratoconjunctivitis sicca: a pooled analysis of phase 2b\/3 and phase 3 studies","volume":"38","author":"Malhotra","year":"2019","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2026.111278_bib34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2017.01.012","article-title":"Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies","volume":"248","author":"Mandal","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.exer.2026.111278_bib35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejpb.2022.10.023","article-title":"An ocular insert with zero-order extended delivery: release kinetics and mathematical models","volume":"181","author":"Mariz","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.exer.2026.111278_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.actbio.2017.01.063","article-title":"Design and optimization of a novel implantation technology in contact lenses for the treatment of dry eye syndrome: in vitro and in vivo evaluation","volume":"53","author":"Maulvi","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.exer.2026.111278_bib37","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1021\/bm5007954","article-title":"Structure of Chitosan determines its interactions with Mucin","volume":"15","author":"Menchicchi","year":"2014","journal-title":"Biomacromolecules"},{"issue":"16","key":"10.1016\/j.exer.2026.111278_bib38","article-title":"ROS-responsive microneedle patches enable peri-lacrimal gland therapeutic administration for long-acting therapy of Sj\u00f6gren's syndrome-related dry eye","volume":"12","author":"Mu","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"7","key":"10.1016\/j.exer.2026.111278_bib39","article-title":"Efficacy and safety of OTX-DED dexamethasone intracanalicular insert in subjects with dry eye disease: a multicenter, randomized, vehicle-controlled phase 2 study","volume":"63","author":"Nijm","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.exer.2026.111278_bib40","article-title":"A retrospective crossover study on cross-linked hyaluronic acid gel (Lacrifill) versus cyclosporine A 0.05% (Restasis) for dry eye disease","volume":"17","author":"Nordin","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.exer.2026.111278_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.929230","article-title":"Can the cGAS-STING pathway play a role in the dry eye?","volume":"13","author":"Ouyang","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.exer.2026.111278_bib42","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/j.jcrs.0000000000001505","article-title":"Effectiveness and safety of a novel crosslinked hyaluronate canalicular gel occlusive device for dry eye","volume":"50","author":"Packer","year":"2024","journal-title":"J. Cataract Refract. Surg."},{"key":"10.1016\/j.exer.2026.111278_bib43","article-title":"Acoltremon ophthalmic solution 0.003% for signs and symptoms of dry eye disease: results of phase 3 pivotal studies COMET-2 and COMET-3","author":"Pattar","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2026.111278_bib44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s42269-023-01123-9","article-title":"Revolutionizing ocular drug delivery: recent advancements in in situ gel technology","volume":"47","author":"Paul","year":"2023","journal-title":"Bull. Natl. Res. Cent."},{"issue":"3","key":"10.1016\/j.exer.2026.111278_bib45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jconrel.2011.06.028","article-title":"Extended cyclosporine delivery by silicone\u2013hydrogel contact lenses","volume":"154","author":"Peng","year":"2011","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.exer.2026.111278_bib48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2024.0101","article-title":"Water-free cyclosporine ophthalmic solution vs vehicle for dry eye disease: a randomized clinical trial","volume":"142","author":"Peng","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.exer.2026.111278_bib47","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.2147\/DDDT.S370559","article-title":"Cyclosporine A (0.05%) ophthalmic gel in the treatment of dry eye disease: a multicenter, randomized, double-masked, phase III, COSMO trial","volume":"16","author":"Peng","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"issue":"3","key":"10.1016\/j.exer.2026.111278_bib46","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.clinthera.2020.12.023","article-title":"Efficacy, safety, and tolerability of a novel cyclosporine, a formulation for dry eye disease: a multicenter phase II clinical study","volume":"43","author":"Peng","year":"2021","journal-title":"Clin. Ther."},{"key":"10.1016\/j.exer.2026.111278_bib49","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.2147\/OPTH.S279051","article-title":"A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments","volume":"14","author":"Periman","year":"2020","journal-title":"Clin. Ophthalmol."},{"issue":"12","key":"10.1016\/j.exer.2026.111278_bib50","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3390\/gels9120933","article-title":"Sustained release of voriconazole using 3D-Crosslinked hydrogel rings and rods for use in corneal drug delivery","volume":"9","author":"Rakhmetova","year":"2023","journal-title":"Gels"},{"issue":"11","key":"10.1016\/j.exer.2026.111278_bib51","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1167\/iovs.12-10025","article-title":"Menthol activation of corneal cool cells induces TRPM8-mediated lacrimation but not nociceptive responses in rodents","volume":"53","author":"Robbins","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2026.111278_bib52","first-page":"10","article-title":"Overcoming the challenges of ophthalmic delivery using aqueous-free technology: redefining dry eye disease","volume":"82","author":"Roesky","year":"2018","journal-title":"ONdrugDelivery"},{"issue":"5","key":"10.1016\/j.exer.2026.111278_bib53","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nn1451","article-title":"PI(4,5)P2 regulates the activation and desensitization of TRPM8 channels through the TRP domain","volume":"8","author":"Roh\u00e1cs","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.exer.2026.111278_bib54","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/jop.2019.0092","article-title":"Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial","volume":"36","author":"Schmidl","year":"2020","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2026.111278_bib55","doi-asserted-by":"crossref","unstructured":"Sheppard JD, Wirta DL, McLaurin E, Boehmer BE, Ciolino JB, Meides AS, Schl\u00fcter T, Ousler GW, Usner D, Kr\u00f6sser S. A water-free 0.1% cyclosporine A solution for treatment of dry eye disease: results of the randomized phase 2B\/3 ESSENCE study.Cornea.2021 October 1;40(10):1290-1297.doi:10.1097\/ICO.0000000000002633. PMID: 34481407; PMCID: PMC8423142.","DOI":"10.1097\/ICO.0000000000002633"},{"key":"10.1016\/j.exer.2026.111278_bib56","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/OPTH.S279364","article-title":"Phase 3 efficacy (Worse-Eye analysis) and long-term safety evaluation of OTX-101 in patients with Keratoconjunctivitis sicca","volume":"15","author":"Sheppard","year":"2021","journal-title":"Clin. Ophthalmol."},{"issue":"3","key":"10.1016\/j.exer.2026.111278_bib57","first-page":"237","article-title":"In situ gelling ophthalmic drug delivery system: an overview and its applications","volume":"9","author":"Sheshala","year":"2015","journal-title":"Recent Pat. Drug Deliv. Formulation"},{"key":"10.1016\/j.exer.2026.111278_bib58","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1021\/bm800276d","article-title":"Why is chitosan mucoadhesive?","volume":"9","author":"Sogias","year":"2008","journal-title":"Biomacromolecules"},{"issue":"9","key":"10.1016\/j.exer.2026.111278_bib59","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1089\/jop.2017.0042","article-title":"Semifluorinated alkane eye drops for treatment of dry eye disease due to meibomian gland disease","volume":"33","author":"Steven","year":"2017","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.exer.2026.111278_bib60","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12951-024-02402-x","article-title":"OCTN2- and ATB0,+-targeted nanoemulsions for improving ocular drug delivery","volume":"22","author":"Tang","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"4","key":"10.1016\/j.exer.2026.111278_bib61","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamaophthalmol.2023.0270","article-title":"Perfluorohexyloctane eye drops for dry eye disease associated with meibomian gland dysfunction in Chinese patients: a randomized clinical trial","volume":"141","author":"Tian","year":"2023","journal-title":"JAMA Ophthalmol."},{"issue":"2","key":"10.1016\/j.exer.2026.111278_bib62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/02713683.2021.1966477","article-title":"The effect of OTX-101 on tear production in patients with severe tear-deficient dry eye disease: a pooled analysis of phase 2b\/3 and phase 3 studies","volume":"47","author":"Toyos","year":"2022","journal-title":"Curr. Eye Res."},{"issue":"4","key":"10.1016\/j.exer.2026.111278_bib63","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3390\/pharmaceutics15041211","article-title":"Semifluorinated alkanes as new drug Carriers-An overview of potential medical and clinical applications","volume":"15","author":"Tsagogiorgas","year":"2023","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.exer.2026.111278_bib64","first-page":"3258","article-title":"Evaluating safety and pharmacokinetics of OTX-CSI, a sustained-release intracanalicular cyclosporine insert in beagles","volume":"61","author":"Vanslette","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2026.111278_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2023.100704","article-title":"In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease","volume":"98","author":"Vittitow","year":"2023","journal-title":"Curr. Ther. Res. Clin. Exp."},{"issue":"3","key":"10.1016\/j.exer.2026.111278_bib66","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.apsb.2016.09.001","article-title":"Nanotechnology-based strategies for treatment of ocular disease","volume":"7","author":"Weng","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.exer.2026.111278_bib68","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jtos.2022.08.003","article-title":"A randomized, vehicle-controlled, phase 2b study of two concentrations of the TRPM8 agonist AR-15512 in the treatment of dry eye disease (COMET-1)","volume":"26","author":"Wirta","year":"2022","journal-title":"Ocul. Surf."},{"issue":"6","key":"10.1016\/j.exer.2026.111278_bib67","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","article-title":"A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease","volume":"126","author":"Wirta","year":"2019","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.exer.2026.111278_bib69","first-page":"571","article-title":"Research progress of drug loaded silicone hydrogel contact lenses","volume":"37","author":"Xue-fang","year":"2024","journal-title":"Polym. Bull."},{"issue":"30","key":"10.1016\/j.exer.2026.111278_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adt8775","article-title":"Thermoresponsive antioxidant metal-free carbon nanodot hydrogel: an effective therapeutic approach for ocular surface disease","volume":"11","author":"Yang","year":"2025","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.exer.2026.111278_bib71","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/jcm10020250","article-title":"Topical TRPM8 agonist for relieving neuropathic ocular pain in patients with dry eye: a pilot study","volume":"10","author":"Yoon","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.exer.2026.111278_bib72","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.exer.2007.11.013","article-title":"MUC19 expression in human ocular surface and lacrimal gland and its alteration in sjogren syndrome patients","volume":"86","author":"Yu","year":"2008","journal-title":"Exp. Eye Res."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483526004343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483526004343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:47:53Z","timestamp":1793944073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483526004343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":71,"alternative-id":["S0014483526004343"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2026.111278","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in long-acting ocular therapies for dry eye disease: Delivery systems, formulations, and clinical perspectives","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2026.111278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111278"}}